Munich Cancer Registry

Munich Cancer Registry at Munich Cancer Center
Marchioninistr. 15
Munich, 81377
Germany

http://www.tumorregister-muenchen.de/en

Cancer statistics: Baseline statistics

C66: Ureteral cancer

Year of diagnosis	1998-2012
Patients	449
Diseases	454
Creation date	03/20/2014
Export date	02/12/2014
Population	4.5 m

BERLIN

GERMANY

BAVARIA

MUNICH

Global Statements about the statistics on the Internet –
Baseline Statistics (grey button ⬜), **Survival** (red button 🟥)

In these analyses, the clinics and physicians of Upper Bavaria and the city and county of Landshut[#], with a total of 4.5 million inhabitants, account for the frequency of cancer diseases[##] and the achieved long term results. Additionally, the long term survival evaluated by the Munich Cancer Registry (MCR) is compared with the results of the population-based registry in the USA (SEER), which is useful for checking the consistency of the data on an international level.

In comparing several tables, inconsistent figures may be detected. This is based on the fact that different patient cohorts are included in the base calculation, for example when proportions of multiple tumors or DCO-cases[###] are concerned. In other cases the individual tumor diagnosis is the basis for calculation, for example with incidence.

The foot notes describe the currentness of the data. The baseline statistics and survival data are updated annually. This yearly analysis comprises the Annual Report of the MCR. The time-delayed acquisition of data and the occasionally high DCO-rates indicate optimizing reserves, among others, because of current financial and legal conditions that hinder the analyses.

Clinics and physicians have access to essentially more detailed data, with which they can check, compare and in the best case optimize their own data and results.

We would be pleased to receive corrections, critique and useful suggestions. Just send an e-mail to tumor@ibe.med.uni-muenchen.de.

Munich Cancer Registry, March 2014

[#] Base data has been collected since 1998. An increase in new diseases is apparent, which is an effect of two extensions in the MCR catchment area (from a base population of 2.51 million to 3.96 in 2002, and to 4.52 million in 2007). Death certificates from 2013 are incorporated into these analyses.

[##] Due to the high frequency and good prognosis of non-malignant skin cancer (C44), no systematic ascertainment is performed for this diagnosis. C44 is not designated as a primary, but rather as a secondary tumor.

[###] DCO (death certificate only) identifies a cancer case that first becomes available to the MCR through the death certificate. A high proportion of DCO cases (≥5%) in particular cancer types indicate insufficient participation of specific cancer specializations.

INCIDENCE

Table 1

Patient cohorts by year of diagnosis including DCO cases
and multiple primaries, and with proportion of deaths and active follow-up

Year of diagnosis	Cases n	DCO cases n	Prop. DCO %	Prop. mult. primaries %	Prop. deaths %	Prop. actively followed %
1998	20			80.0	85.0	100.0
1999	11			72.7	81.8	100.0
2000	12			66.7	58.3	100.0
2001	24			62.5	95.8	100.0
2002	30			56.7	76.7	100.0 #
2003	19			57.9	52.6	100.0 #
2004	24			70.8	66.7	91.7 #
2005	39			66.7	66.7	94.9 #
2006	36			75.0	66.7	94.4 #
2007	35			71.4	54.3	80.0 # ##
2008	39			64.1	51.3	76.9
2009	42			71.4	52.4	73.8
2010	48	1	2.1	77.1	56.3	83.3
2011	43			76.7	25.6	81.4
2012	32	1	3.1	71.9	21.9	100.0 ###
1998–2012	454	2	0.4	70.0	57.5	89.2

\#   The increases of incident cases in 2002 and 2007 reflect the expansion to additional registry areas.

\##   Since 2007 the percentage of actively followed patients sharply declined compared to the previous years. This is a consequence of ambiguous data protection rules that currently forbid cancer registries in Bavaria to obtain the essential life status informations from competent registration offices.

\###   Please be aware that data of recent annual patient cohorts may not yet be fully processed. Therefore, the presented figures and tables are potentially related to different time periods as pointed out in the respective headlines or legends.

Table 1a

Patient cohorts by year of diagnosis and gender
including DCO cases

Year of diagnosis	All n	Males n	Females n	Prop. males %
1998	20	13	7	65.0
1999	11	7	4	63.6
2000	12	7	5	58.3
2001	24	13	11	54.2
2002	30	17	13	56.7
2003	19	10	9	52.6
2004	24	15	9	62.5
2005	39	28	11	71.8
2006	36	23	13	63.9
2007	35	27	8	77.1
2008	39	19	20	48.7
2009	42	28	14	66.7
2010	48	34	14	70.8
2011	43	25	18	58.1
2012	32	17	15	53.1
1998-2012	454	283	171	62.3

Table 2

Incidence measures by year of diagnosis and gender including DCO cases
(with respect to registry area expansion from 2.51 to 3.96 m as of 2002,
and from 3.96 to 4.52 m as of 2007, respectively)

Year of diagnosis	Males n	Females n	Males Inc. raw	Fem. Inc. raw	Males Inc. WS	Fem. Inc. WS	Males Inc. ES	Fem. Inc. ES	Males Inc. BRD-S	Fem. Inc. BRD-S
1998	13	7	1.2	0.6	0.8	0.3	1.1	0.4	1.5	0.5
1999	7	4	0.6	0.3	0.4	0.1	0.6	0.2	0.8	0.2
2000	7	5	0.6	0.4	0.4	0.2	0.6	0.2	0.8	0.4
2001	13	11	1.1	0.9	0.6	0.4	1.0	0.6	1.4	0.8
2002	17	13	0.9	0.7	0.5	0.3	0.8	0.5	1.0	0.6
2003	10	9	0.5	0.5	0.2	0.2	0.4	0.3	0.6	0.4
2004	15	9	0.8	0.5	0.4	0.2	0.6	0.3	0.9	0.4
2005	28	11	1.5	0.6	0.8	0.2	1.2	0.4	1.6	0.4
2006	23	13	1.2	0.6	0.6	0.2	0.9	0.4	1.2	0.5
2007	27	8	1.2	0.3	0.6	0.1	0.9	0.2	1.2	0.3
2008	19	20	0.9	0.9	0.5	0.3	0.7	0.5	0.9	0.7
2009	28	14	1.3	0.6	0.6	0.2	0.9	0.3	1.2	0.5
2010	34	14	1.5	0.6	0.6	0.3	1.0	0.4	1.5	0.5
2011	25	18	1.1	0.8	0.6	0.2	0.8	0.4	1.1	0.5
2012	17	15	0.7	0.6	0.3	0.2	0.5	0.3	0.8	0.5
1998-2012	283	171	1.0	0.6	0.5	0.2	0.8	0.3	1.1	0.5

The computation of the incidence measures includes all primaries, irrespective of first or subsequent malignancy.

Table 3

Age distribution parameters by year of diagnosis (All)
(incl. DCO)

Year of diagnosis	Cases n	Mean	Std. dev.	Min.	Max.	10%	25%	Median 50%	75%	90%
1998	20	70.4	9.0	49.0	83.3	57.1	66.9	70.0	78.3	81.1
1999	11	74.4	12.9	49.4	89.5	55.0	69.7	76.5	87.7	87.8
2000	12	71.2	10.4	45.2	81.7	62.8	66.7	73.1	79.8	80.6
2001	24	73.6	7.4	57.2	87.5	61.8	70.4	74.6	77.9	80.5
2002	30	70.0	9.9	51.7	91.1	56.6	62.3	71.5	75.3	82.7
2003	19	74.5	8.6	56.6	87.3	60.9	69.8	77.4	80.7	85.0
2004	24	72.8	11.4	46.3	94.6	54.9	69.6	74.2	79.8	84.2
2005	39	70.2	12.2	38.2	93.3	53.1	65.8	70.5	78.2	89.2
2006	36	72.7	9.4	50.5	88.7	59.2	66.4	72.7	80.3	84.6
2007	35	72.8	8.2	53.2	87.8	62.9	67.6	74.0	76.4	83.7
2008	39	72.1	9.4	49.3	87.2	61.2	64.5	73.5	79.7	84.9
2009	42	72.8	10.7	29.1	89.0	60.2	68.6	72.5	80.6	83.9
2010	48	74.0	8.8	52.4	92.7	60.0	70.0	74.0	80.4	84.6
2011	43	72.7	10.0	50.3	89.7	59.1	64.9	72.9	80.9	84.8
2012	32	75.1	9.3	53.2	92.8	63.2	67.8	77.2	81.8	83.5
1998-2012	454	72.6	9.8	29.1	94.6	59.2	67.3	73.6	79.7	84.2

Table 3a

Age distribution parameters by year of diagnosis (MALES)
(incl. DCO)

Year of diagnosis	Cases n	Mean	Std. dev.	Min.	Max.	10%	25%	Median 50%	75%	90%
1998	13	69.5	9.1	49.0	81.7	55.6	67.8	69.9	74.9	80.4
1999	7	70.5	14.1	49.4	89.5	49.4	55.0	72.3	80.9	89.5
2000	7	68.9	11.5	45.2	80.3	45.2	66.2	73.0	76.6	80.3
2001	13	73.7	6.6	61.6	86.8	64.0	70.5	74.8	76.9	78.0
2002	17	69.2	9.9	52.0	91.1	55.1	62.3	70.9	74.4	80.3
2003	10	74.4	10.8	56.6	87.3	58.8	63.9	79.1	81.2	86.1
2004	15	73.4	9.8	54.9	86.9	55.9	69.8	74.9	80.1	84.2
2005	28	70.5	12.1	47.6	93.3	53.1	65.8	69.5	78.1	89.2
2006	23	71.4	8.0	50.5	84.3	64.0	65.8	71.2	79.7	80.5
2007	27	72.2	8.7	53.2	87.8	62.9	66.9	72.1	76.3	86.4
2008	19	69.2	10.7	49.3	87.2	51.3	61.7	67.8	78.3	85.9
2009	28	70.1	11.4	29.1	89.0	59.5	64.5	70.2	77.1	82.9
2010	34	76.3	7.6	60.0	92.7	67.4	70.4	76.8	82.1	85.1
2011	25	69.9	9.7	50.3	84.9	58.5	62.3	68.0	79.5	82.6
2012	17	72.5	8.9	53.2	83.5	61.7	67.3	75.0	77.4	83.4
1998-2012	283	71.6	9.8	29.1	93.3	58.7	66.0	72.2	79.2	83.4

Table 3b

Age distribution parameters by year of diagnosis (FEMALES)
(incl. DCO)

Year of diagnosis	Cases n	Mean	Std. dev.	Min.	Max.	10%	25%	Median 50%	75%	90%
1998	7	72.2	9.1	58.5	83.3	58.5	64.7	72.4	80.2	83.3
1999	4	81.2	7.8	72.3	87.8	72.3	74.6	82.3	87.7	87.8
2000	5	74.3	8.7	62.8	81.7	62.8	67.3	79.2	80.6	81.7
2001	11	73.5	8.6	57.2	87.5	61.8	70.4	73.7	79.9	80.5
2002	13	71.1	10.1	51.7	87.0	58.6	65.3	72.7	76.0	85.0
2003	9	74.6	6.0	64.1	83.1	64.1	71.0	75.0	79.2	83.1
2004	9	71.8	14.3	46.3	94.6	46.3	69.4	73.5	79.4	94.6
2005	11	69.3	13.2	38.2	91.0	59.5	65.4	71.6	78.2	78.2
2006	13	74.9	11.5	52.1	88.7	58.1	71.9	75.1	84.6	87.4
2007	8	74.7	6.8	60.3	82.8	60.3	72.6	75.7	78.8	82.8
2008	20	74.7	7.3	63.4	85.7	64.1	68.6	74.5	81.0	84.5
2009	14	78.4	6.6	66.0	87.2	67.9	74.3	79.7	83.9	84.0
2010	14	68.5	9.4	52.4	79.8	54.6	59.4	72.4	75.6	78.5
2011	18	76.7	9.2	56.8	89.7	59.1	71.6	76.6	84.6	88.0
2012	15	78.0	9.2	56.7	92.8	67.2	69.7	80.0	83.3	90.2
1998-2012	171	74.2	9.6	38.2	94.6	60.3	69.2	75.0	80.6	84.9

Table 4

Age distribution by 5-year age group and gender for period 1998-2012
(incl. DCO)

Age at diagnosis Years	Cases n	%	Cum.%	Males n	%	Cum.%	Females n	%	Cum.%
25-29	1	0.2	0.2	1	0.4	0.4			0.0
30-34	0	0.0	0.2			0.4			0.0
35-39	1	0.2	0.4			0.4	1	0.6	0.6
40-44	0	0.0	0.4			0.4			0.6
45-49	7	1.5	2.0	6	2.1	2.5	1	0.6	1.2
50-54	17	3.7	5.7	12	4.2	6.7	5	2.9	4.1
55-59	24	5.3	11.0	14	4.9	11.7	10	5.8	9.9
60-64	41	9.0	20.0	30	10.6	22.3	11	6.4	16.4
65-69	70	15.4	35.5	52	18.4	40.6	18	10.5	26.9
70-74	97	21.4	56.8	58	20.5	61.1	39	22.8	49.7
75-79	89	19.6	76.4	50	17.7	78.8	39	22.8	72.5
80-84	71	15.6	92.1	41	14.5	93.3	30	17.5	90.1
85+	36	7.9	100.0	19	6.7	100.0	17	9.9	100.0
All ages	454	100.0		283	100.0		171	100.0	

Included in the statistics are 130.8% multiple primaries in males and 98.2% in females.

Table 5

Age-specific incidence, DCO rate and proportion of all cancers
for period 1998-2012

Age at diagnosis Years	Males n	Females n	Males Age-spec. incid.	Females Age-spec. incid.	Males DCO rate n=0 %	Females DCO rate n=2 %	Males Prop.all cancers n=146755 %	Females Prop.all cancers n=142297 %
0- 4			0.0	0.0				
5- 9			0.0	0.0				
10-14			0.0	0.0				
15-19			0.0	0.0				
20-24			0.0	0.0				
25-29	1		0.1	0.0			0.1	
30-34			0.0	0.0				
35-39		1	0.0	0.0				0.0
40-44			0.0	0.0				
45-49	6	1	0.3	0.0			0.1	0.0
50-54	12	5	0.6	0.3			0.1	0.0
55-59	13	10	0.8	0.6			0.1	0.1
60-64	30	11	1.8	0.6			0.1	0.1
65-69	52	18	3.5	1.1			0.2	0.1
70-74	57	39	4.9	2.8			0.2	0.2
75-79	50	38	6.6	3.5		2.6	0.3	0.2
80-84	40	30	8.8	3.5		3.3	0.3	0.2
85+	19	17	6.1	2.1			0.2	0.1
All ages	280	170			0.0	1.2	0.2	0.1
Incidence								
Raw			1.0	0.6				
WS			0.5	0.2				
ES			0.8	0.3				
BRD-S			1.1	0.5				

The age-specific incidence characterizes the disease risk in a particular age group. The age distribution depends on the patient population frequency in each age group and reflects the tangible clinical picture of everyday patients care (see following chart).

Table 6a

Standardized incidence ratio (SIR, with 95% confidence limits),
excess absolute risk (EAR) and DCO rate of second primaries
for period 1998-2012
MALES

Diagnosis		Observed n	Expected n	SIR	LCL 95%	UCL 95%		EAR	DCO %
C15	Oesophagus	3	0.2	14.4	3.0	42.1	#	43.8	33.3
C33-C34	Lung	6	1.6	3.9	1.4	8.4	#	69.8	16.7
C61	Prostate	15	3.9	3.8	2.1	6.3	#	173.9	6.7
C64	Kidney	6	0.4	13.8	5.1	30.0	#	87.3	66.7
C65	Renal pelvis	21	0.1	359.0	222.2	548.8	#	328.6	
C67	Bladder	30	0.7	46.0	31.1	65.7	#	460.5	
Other primaries		9	3.9	2.3	1.0	4.4	#	79.6	11.1
Not observed		0	2.7	0.0	0.0	1.4		-41.6	
All mult. primaries		90	13.4	6.7	5.4	8.3	#	1202	8.9

Patients	207
Mean age at second malignancy (years)	72.2
Person-years	637
Mean observation time (years)	3.1
Median observation time (years)	2.2

The occurrence of second malignancy is statistically significant.

Observed second primaries with count 1 are pooled in category "Other primaries".

Table 6b

Standardized incidence ratio (SIR, with 95% confidence limits),
excess absolute risk (EAR) and DCO rate of second primaries
for period 1998-2012
FEMALES

Diagnosis	Observed n	Expected n	SIR	LCL 95%	UCL 95%		EAR	DCO %
C33-C34 Lung	2	0.4	5.0	0.6	18.0		38.0	
C50 Breast	3	1.6	1.9	0.4	5.6		34.2	
C64 Kidney	4	0.2	24.8	6.7	63.4	#	91.4	100.0
C65 Renal pelvis	9	0.0	427.2	195.3	810.9	#	213.8	
C67 Bladder	15	0.1	112.9	63.2	186.2	#	354.0	
Other primaries	5	0.9	5.3	1.7	12.4	#	96.7	
Not observed	0	2.8	0.0	0.0	1.3		-65.6	
All mult. primaries	38	6.0	6.4	4.5	8.7	#	762.6	10.5

```
Patients                                 128
Mean age at second malignancy (years)    74.2
Person-years                             420
Mean observation time (years)            3.3
Median observation time (years)          1.9
```

The occurrence of second malignancy is statistically significant.

Observed second malignancies with count 1 are pooled in category "Other primaries".

C66: Malignant neoplasm of ureter
Age distribution and age-specific incidence 1998 - 2012 (Males: 280, Females: 170)

Figure 7. Age distribution and age-specific incidence

C66: Malignant neoplasm of ureter
Age-specific incidence in international comparison

Figure 7a. Age-specific incidence in MCR registry areas compared to SEER (Surveillance, Epidemiology, and End Results, USA).

Reference:

Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Incidence - SEER 18 Regs Research Data, released April 2012, based on the November 2011 submission. http://www.seer.cancer.gov.

C66: Malignant neoplasm of ureter
Cumulative follow-up years since diagnosis for period 1998 - 2012 (excl. DCO)

			Target			Actual
Gender	n	Sum	Median		Sum	Median
All patients						
Males	180	646	2.8		624	2.5
Females	108	431	2.5		414	2.4
Patients alive						
Males	95	471	3.9		449	3.7
Females	54	315	5.6		297	4.5

Figure 8. Cumulative follow-up years depending on time since diagnosis

The increase of the lost to follow-up rate can be interpreted as a consequence of a declining number of survivors over time.

Average incidence (world standard population) 2003 - 2008: Males

Average incidence (world standard population) 2003 - 2008: Females

Figure 9a. Map of cancer incidence (world standard population, incl. DCO cases) by county averaged for period 2003 to 2008. According to their individual incidence rates, the counties are displayed in different red and blue color temperatures where the fine white color indicates the population mean (males 0.5/100,000 WS N=114, females 0.2/100,000 WS N=66). Since cancer data are not available in some counties until 2007, the local incidence rates were not calculated, and the map tiles show as shaded.

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 63,131 female residents (averaged) in the period from 2003 to 2008 a total of 2 women were identified with newly diagnosed ureteral cancer. Therefore, the mean incidence rate for this cancer type in this area can be calculated at 0.2/100,000 (world standard population). Though, the value of this parameter may vary with an underlying probability of 99% between 0.0 and 1.0/100,000.

Standardized incidence ratio (SIR) 2003 - 2008: Males

Standardized incidence ratio (SIR) 2003 - 2008: Females

Figure 9b. Map of standardized incidence ratio (SIR, incl. DCO cases) by county averaged for period 2003 to 2008. According to their individual SIR values, the counties are displayed in different red and blue color temperatures where the fine white color indicates the population overall of 1.0 (males N=114, females N=66). Since cancer data are not available in some counties until 2007, the local SIR values were not calculated, and the map tiles show as shaded.

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 63,131 female residents (averaged) in the period from 2003 to 2008 a total of 2 women were identified with newly diagnosed ureteral cancer. Therefore, the mean standardized incidence ratio (SIR) for this cancer type in this area can be calculated at 1.05. Though, the value of this parameter may vary with an underlying probability of 99% between 0.05 and 4.88, and is therefore not statistically striking.

MORTALITY

Table 10a

Patient cohorts of incident cancers by year of diagnosis, follow-up status,
proportion of DCO, deaths among the annual cohorts,
and proportion of available death certificates
(with respect to registry area expansion from 2.51 to 3.96 m as of 2002,
and from 3.96 to 4.52 m as of 2007, respectively)

Year of diagnosis	Incident cases n	Prop. actively followed %	Prop. DCO %	Deaths n	Prop. deaths %	Prop. deaths with death certific. %
1998	20	100.0		17	85.0	100.0
1999	11	100.0		9	81.8	100.0
2000	12	100.0		7	58.3	100.0
2001	24	100.0		23	95.8	100.0
2002	30	100.0		23	76.7	95.7
2003	19	100.0		10	52.6	100.0
2004	24	91.7		16	66.7	93.8
2005	39	94.9		26	66.7	96.2
2006	36	94.4		24	66.7	100.0
2007	35	80.0		19	54.3	100.0
2008	39	76.9		20	51.3	100.0
2009	42	73.8		22	52.4	100.0
2010	48	83.3	2.1	27	56.3	100.0
2011	43	81.4		11	25.6	100.0
2012	32	100.0	3.1	7	21.9	71.4
1998-2012	454	89.2	0.4	261	57.5	98.1

Table 10b

Annual cohorts of incident cancers and deaths, proportion of death certificates
and cases deceased the same year of cancer diagnosis
(incl. DCO)
(with respect to registry area expansion from 2.51 to 3.96 m as of 2002,
and from 3.96 to 4.52 m as of 2007, respectively)

Year of diagnosis/ death	Incident cases n	Deaths n	Prop. deaths with death certific. %	Deaths in same year n	Prop. deaths in same year %
1998	20	13	84.6	3	15.0
1999	11	8	100.0	1	9.1
2000	12	9	100.0	2	16.7
2001	24	12	100.0	3	12.5
2002	30	10	100.0	1	3.3
2003	19	25	96.0	4	21.1
2004	24	13	100.0	1	4.2
2005	39	16	100.0	4	10.3
2006	36	24	95.8	2	5.6
2007	35	21	95.2	1	2.9
2008	39	33	100.0	2	5.1
2009	42	33	100.0	7	16.7
2010	48	27	100.0	3	6.3
2011	43	43	100.0	6	14.0
2012	32	25	100.0	3	9.4
1998-2012	454	312	98.4	43	9.5

Table 10c

Annual cohorts of deaths, proportion of cancer-related and not cancer-
related deaths, and cancer recorded on death certificates
(incl. DCO)
(with respect to registry area expansion from 2.51 to 3.96 m as of 2002,
and from 3.96 to 4.52 m as of 2007, respectively)

Year of death	Deaths n	Prop. cancer-related %	Prop. not cancer-related %	Prop. cancer recorded on death certificate %
1998	13	61.5	38.5	81.8
1999	8	75.0	25.0	87.5
2000	9	77.8	22.2	88.9
2001	12	75.0	25.0	83.3
2002	10	80.0	20.0	100.0
2003	25	84.0	16.0	87.5
2004	13	69.2	30.8	69.2
2005	16	81.3	18.8	81.3
2006	24	75.0	25.0	82.6
2007	21	85.7	14.3	95.0
2008	33	69.7	30.3	72.7
2009	33	84.8	15.2	90.9
2010	27	81.5	18.5	88.9
2011	43	79.1	20.9	88.4
2012	25	68.0	32.0	80.0
1998-2012	312	77.2	22.8	85.0

Table 11a

Means of age at death according to the grouping in Table 10
MALES

Year of death	Deaths n	Age at death (all causes) Years	Age at death (cancer-related) Years	Age at death (not cancer-related) Years	Age at death (according to death certificate) Years
1998	4	65.8	67.3	61.3	67.3
1999	5	72.6	73.5	69.1	72.6
2000	6	68.4	66.8	71.8	67.5
2001	8	75.6	75.6	75.6	75.6
2002	6	75.5	73.8	78.8	75.5
2003	17	75.7	74.3	82.3	74.9
2004	7	80.0	77.5	94.7	77.5
2005	6	77.8	74.4	84.5	77.9
2006	15	77.6	76.4	80.9	77.2
2007	18	73.1	71.9	79.2	72.4
2008	19	77.6	75.8	80.1	76.5
2009	24	75.6	75.5	75.8	75.3
2010	16	75.2	74.8	78.1	75.7
2011	27	80.4	79.5	83.7	79.5
2012	18	77.8	77.1	80.0	77.4
1998-2012	196	76.3	75.3	79.6	75.8

Deaths of patients are considered to be cancer-related, in case that fact was recorded on the death certificate, or patients had suffered from metastasis or recurrence.

Table 11b

Means of age at death according to the grouping in Table 10
FEMALES

Year of death	Deaths n	Age at death (all causes) Years	Age at death (cancer-related) Years	Age at death (not cancer-related) Years	Age at death (according to death certificate) Years
1998	9	77.1	71.1	84.5	72.7
1999	3	78.7	79.5	77.2	79.5
2000	3	75.8	75.8		75.8
2001	4	76.7	69.6	83.7	69.6
2002	4	74.8	74.8		74.8
2003	8	79.0	77.6	89.2	79.0
2004	6	79.4	78.3	80.6	78.3
2005	10	77.6	77.6	77.2	76.1
2006	9	79.3	79.3	79.0	77.9
2007	3	77.1	77.1		77.1
2008	14	78.3	77.2	84.9	78.2
2009	9	76.0	77.4	65.0	76.0
2010	11	75.7	75.9	75.4	74.9
2011	16	81.3	81.2	81.8	81.6
2012	7	80.5	77.5	82.7	79.0
1998-2012	116	78.2	77.4	80.9	77.3

By 2010, life expectancy for a newborn male in Germany is 77.5 years compared with 82.6 years for his female counterpart.

Deaths of patients are considered to be cancer-related, in case that fact was recorded on the death certificate, or patients had suffered from metastasis or recurrence.

Table 12a

Mortality measures (cancer-related death) and mortality-incidence-index
by year of death
MALES

Year of death	Deaths n	Mort. raw	MI-Index raw	Mort. WS	MI-Index WS	Mort. ES	MI-Index ES	Mort. BRD-S	MI-Index BRD-S
1998	3	0.3	0.23	0.2	0.24	0.2	0.22	0.3	0.19
1999	4	0.4	0.57	0.2	0.43	0.3	0.52	0.6	0.66
2000	4	0.4	0.57	0.2	0.46	0.3	0.54	0.4	0.54
2001	7	0.6	0.54	0.3	0.54	0.5	0.53	0.8	0.57
2002	4	0.2	0.24	0.1	0.23	0.2	0.23	0.2	0.23
2003	14	0.7	1.40	0.4	1.43	0.6	1.46	0.9	1.46
2004	6	0.3	0.40	0.2	0.40	0.3	0.42	0.4	0.41
2005	4	0.2	0.14	0.1	0.14	0.2	0.14	0.2	0.13
2006	11	0.6	0.50	0.2	0.44	0.5	0.53	0.7	0.61
2007	15	0.7	0.58	0.3	0.59	0.5	0.62	0.7	0.64
2008	11	0.5	0.58	0.2	0.44	0.4	0.51	0.6	0.64
2009	20	0.9	0.71	0.4	0.63	0.6	0.68	0.8	0.70
2010	14	0.6	0.41	0.3	0.46	0.4	0.45	0.6	0.43
2011	21	0.9	0.88	0.3	0.61	0.6	0.74	0.9	0.81
2012	14	0.6	0.82	0.3	0.75	0.4	0.79	0.6	0.73
1998-2012	152	0.6	0.54	0.3	0.50	0.4	0.54	0.6	0.57

Table 12b

Mortality measures (cancer-related death) and mortality-incidence-index
by year of death
FEMALES

Year of death	Deaths n	Mort. raw	MI-Index raw	Mort. WS	MI-Index WS	Mort. ES	MI-Index ES	Mort. BRD-S	MI-Index BRD-S
1998	5	0.4	0.71	0.2	0.82	0.3	0.76	0.4	0.72
1999	2	0.2	0.50	0.1	0.66	0.1	0.62	0.2	0.72
2000	3	0.2	0.60	0.1	0.70	0.2	0.67	0.2	0.52
2001	2	0.2	0.18	0.1	0.18	0.1	0.17	0.1	0.18
2002	4	0.2	0.31	0.1	0.23	0.1	0.25	0.2	0.32
2003	7	0.4	0.78	0.1	0.67	0.2	0.67	0.2	0.64
2004	3	0.2	0.33	0.0	0.19	0.1	0.22	0.1	0.28
2005	9	0.5	0.82	0.2	0.62	0.3	0.68	0.3	0.73
2006	7	0.3	0.54	0.1	0.42	0.2	0.45	0.2	0.46
2007	3	0.1	0.38	0.0	0.37	0.1	0.33	0.1	0.33
2008	12	0.5	0.60	0.2	0.51	0.3	0.54	0.4	0.56
2009	8	0.3	0.57	0.1	0.66	0.2	0.64	0.2	0.50
2010	8	0.3	0.57	0.1	0.45	0.2	0.47	0.3	0.50
2011	13	0.6	0.72	0.1	0.54	0.2	0.60	0.4	0.72
2012	3	0.1	0.21	0.0	0.22	0.1	0.22	0.1	0.20
1998-2012	89	0.3	0.52	0.1	0.45	0.2	0.47	0.2	0.48

Table 13

Age distribution of age at death (cancer-related) for period 1998-2012
(**incl. multiple primaries**)

Age at death Years	Cases n	%	Cum.%	Males n	%	Cum.%	Females n	%	Cum.%
50-54	5	2.1	2.1	4	2.6	2.6	1	1.1	1.1
55-59	11	4.5	6.6	8	5.2	7.8	3	3.4	4.5
60-64	17	7.0	13.6	10	6.5	14.3	7	7.9	12.4
65-69	26	10.7	24.3	17	11.0	25.3	9	10.1	22.5
70-74	45	18.5	42.8	32	20.8	46.1	13	14.6	37.1
75-79	50	20.6	63.4	34	22.1	68.2	16	18.0	55.1
80-84	44	18.1	81.5	24	15.6	83.8	20	22.5	77.5
85+	45	18.5	100.0	25	16.2	100.0	20	22.5	100.0
All ages	243	100.0		154	100.0		89	100.0	

Included in the statistics are 130.8% multiple primaries in males and 98.2% in females.

Table 14

Age-specific mortality (cancer-related) and proportion of all cancers
for period 1998-2012
(**incl. multiple primaries**)

Age at death Years	Males n	Females n	Males Age-spec. mortal.	MI-index	Females Age-spec. mortal.	MI-index	Males Prop.all cancers %	Females Prop.all cancers %
0- 4			0.0		0.0			
5- 9			0.0		0.0			
10-14			0.0		0.0			
15-19			0.0		0.0			
20-24			0.0		0.0			
25-29			0.0		0.0			
30-34			0.0		0.0			
35-39			0.0		0.0			
40-44			0.0		0.0			
45-49			0.0		0.0			
50-54	4	1	0.2	0.33	0.1	0.20	0.1	0.0
55-59	8	3	0.5	0.57	0.2	0.30	0.1	0.1
60-64	10	7	0.6	0.33	0.4	0.64	0.1	0.1
65-69	17	9	1.2	0.33	0.6	0.50	0.2	0.1
70-74	32	13	2.8	0.55	0.9	0.33	0.3	0.1
75-79	34	16	4.5	0.68	1.5	0.41	0.3	0.2
80-84	24	20	5.3	0.59	2.3	0.67	0.2	0.2
85+	25	20	8.1	1.32	2.4	1.18	0.3	0.2
All ages	154	89					0.2	0.1
Mortality								
Raw			0.6	0.54	0.3	0.52		
WS			0.3	0.50	0.1	0.45		
ES			0.4	0.54	0.2	0.47		
BRD-S			0.6	0.57	0.2	0.48		
PYLL-70								
per 100,000			1.2		0.5			
ES			1.0		0.4			
AYLL-70			7.4		6.5			

The rates underestimate the prognosis if other synchronous cancers are prognostic unfavorable.

Table 15a

Multiple primaries in deaths in period 1998-2012
MALES

Diagnosis		Total n	Total %↓	Pre n	Pre ←%	Syn-chron ±30d n	Syn-chron ±30d ←%	Post n	Post ←%
C12-C13	Hypopharynx	2	1.0	1	50.0			1	50.0
C15	Oesophagus	4	1.9	1	25.0			3	75.0
C16	Stomach	2	1.0					2	100.0
C18	Colon	7	3.4	4	57.1	1	14.3	2	28.6
C19-C20	Rectum	5	2.4	3	60.0	1	20.0	1	20.0
C32	Larynx	3	1.4	1	33.3	1	33.3	1	33.3
C33-C34	Lung	8	3.9	1	12.5	1	12.5	6	75.0
C43	Malign. melanoma	3	1.4	2	66.7			1	33.3
C44	Skin others	6	2.9	6	100.0				
C61	Prostate	17	8.2	10	58.8	3	17.6	4	23.5
C64	Kidney	13	6.3	5	38.5	2	15.4	6	46.2
C65	Renal pelvis	24	11.6	3	12.5	13	54.2	8	33.3
C66	Ureter	7	3.4			3	42.9	4	57.1
C67	Bladder	84	40.6	37	44.0	10	11.9	37	44.0
C68	Urethra	3	1.4	1	33.3			2	66.7
C68	Urinary org.	6	2.9	1	16.7	2	33.3	3	50.0
C82-C85	NHL	3	1.4	2	66.7	1	33.3		
C91-C96	Leukaemia	3	1.4	1	33.3			2	66.7
Other primaries		7	3.4	4	57.1			3	42.9
All mult. primaries		207	100.0	83	40.1	38	18.4	86	41.5

Multiple primaries with number of cases n<2 are pooled in category "Other primaries".

ICD-10 C44 (Other malignant neoplasms of skin) is not systematically recorded by MCR and therefore not considered for evaluation as a particular primary but at least as a multiple malignancy.

Table 15b

Multiple primaries in deaths in period 1998-2012
FEMALES

Diagnosis		Total n	Total %↓	Pre n	Pre ←%	Syn-chron ±30d n	Syn-chron ±30d ←%	Post n	Post ←%
C15	Oesophagus	1	1.1					1	100.0
C16	Stomach	2	2.1					2	100.0
C18	Colon	8	8.5	5	62.5	2	25.0	1	12.5
C19-C20	Rectum	1	1.1					1	100.0
C33-C34	Lung	3	3.2			1	33.3	2	66.7
C44	Skin others	1	1.1					1	100.0
C48	Peritoneal	1	1.1			1	100.0		
C50	Breast	9	9.6	6	66.7			3	33.3
C53	Cervix uteri	3	3.2	3	100.0				
C54	Corpus uteri	2	2.1	2	100.0				
C56	Ovary	1	1.1	1	100.0				
C64	Kidney	6	6.4	1	16.7	2	33.3	3	50.0
C65	Renal pelvis	15	16.0	3	20.0	8	53.3	4	26.7
C66	Ureter	2	2.1			1	50.0	1	50.0
C67	Bladder	32	34.0	7	21.9	6	18.8	19	59.4
C68	Urinary org.	3	3.2	1	33.3	1	33.3	1	33.3
C73	Thyroid	1	1.1	1	100.0				
C76-C79	CUP	1	1.1					1	100.0
C82-C85	NHL	1	1.1	1	100.0				
C90	Mult. myeloma	1	1.1					1	100.0
All mult. primaries		94	100.0	31	33.0	22	23.4	41	43.6

ICD-10 C44 (Other malignant neoplasms of skin) is not systematically recorded by MCR and therefore not considered for evaluation as a particular primary but at least as a multiple malignancy.

Table 16

Age-specific mortality (cancer-related) and proportion of all cancers
for period 1998-2012
(**Singular primaries only ***)

Age at death Years	Males n	Females n	Males Age-spec. mortal.	MI-index	Females Age-spec. mortal.	MI-index	Males Prop.all cancers %	Females Prop.all cancers %
0- 4			0.0		0.0			
5- 9			0.0		0.0			
10-14			0.0		0.0			
15-19			0.0		0.0			
20-24			0.0		0.0			
25-29			0.0		0.0			
30-34			0.0		0.0			
35-39			0.0		0.0			
40-44			0.0		0.0			
45-49			0.0		0.0			
50-54	2	1	0.1	0.22	0.1	0.50	0.1	0.0
55-59	5	1	0.3	0.71	0.1	0.20	0.1	0.0
60-64	5	3	0.3	0.31	0.2	0.60	0.1	0.1
65-69	10	7	0.7	0.42	0.4	0.64	0.1	0.1
70-74	10	6	0.9	0.45	0.4	0.25	0.1	0.1
75-79	14	11	1.9	0.74	1.0	0.50	0.2	0.1
80-84	8	11	1.8	0.44	1.3	0.73	0.1	0.1
85+	11	12	3.5	1.10	1.5	1.09	0.2	0.1
All ages	65	52					0.1	0.1
Mortality								
Raw			0.2	0.50	0.2	0.54		
WS			0.1	0.47	0.1	0.47		
ES			0.2	0.50	0.1	0.49		
BRD-S			0.3	0.52	0.1	0.51		
PYLL-70								
per 100,000			0.6		0.3			
ES			0.6		0.2			
AYLL-70			7.3		5.8			

* See corresponding tables with multiple primaries.

Table 17

Age-specific mortality (cancer-related) and proportion of all cancers
for period 1998-2012
(**Single primaries only ***)

Age at death Years	Males n	Females n	Males Age-spec. mortal.	MI-index	Females Age-spec. mortal.	MI-index	Males Prop.all cancers %	Females Prop.all cancers %
0- 4			0.0		0.0			
5- 9			0.0		0.0			
10-14			0.0		0.0			
15-19			0.0		0.0			
20-24			0.0		0.0			
25-29			0.0		0.0			
30-34			0.0		0.0			
35-39			0.0		0.0			
40-44			0.0		0.0			
45-49			0.0		0.0			
50-54	2	1	0.1	0.33	0.1	1.00	0.1	0.0
55-59	1		0.1	0.14	0.0		0.0	
60-64	3	2	0.2	0.43	0.1	1.00	0.0	0.0
65-69	4	6	0.3	0.29	0.4	0.67	0.1	0.1
70-74	5	3	0.4	0.50	0.2	0.18	0.1	0.0
75-79	3	7	0.4	0.27	0.6	0.47	0.0	0.1
80-84	4	6	0.9	0.33	0.7	0.67	0.1	0.1
85+	5	6	1.6	1.67	0.7	0.86	0.1	0.1
All ages	27	31					0.1	0.1
Mortality								
Raw			0.1	0.38	0.1	0.48		
WS			0.0	0.36	0.0	0.45		
ES			0.1	0.38	0.1	0.45		
BRD-S			0.1	0.37	0.1	0.46		
PYLL-70								
per 100,000			0.3		0.2			
ES			0.3		0.2			
AYLL-70			8.0		5.3			

* See corresponding tables with multiple primaries.

C66: Malignant neoplasm of ureter
Age distribution and age-specific mortality 1998 - 2012 (Males: 152, Females: 89)

Figure 18. Distribution of age at death (bars) and age-specific mortality (all patients: solid line, patients with single primaries: dotted line). The age-specific incidence is additionally plotted for comparison (dashed line).

The difference between age at diagnosis (Table 3) and age at ureteral cancer-related death (see Table 10) should be considered.

Average mortality (world standard population) 2003 - 2008: Males

Average mortality (world standard population) 2003 - 2008: Females

Figure 19a. Map of cancer mortality (world standard population) by county averaged for period 2003 to 2008. According to their individual mortality rates, the counties are displayed in different red and blue color temperatures where the fine white color indicates the population mean (males 0.2/100,000 WS N=55, females 0.1/100,000 WS N=39). Since cancer data are not available in some counties until 2007, the local mortality rates were not calculated, and the map tiles show as shaded.

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 63,131 female residents (averaged) in the period from 2003 to 2008 a total of 1 women died from ureteral cancer. Therefore, the mean mortality rate for this cancer type in this area can be calculated at 0.2/100,000 (world standard population). Though, the value of this parameter may vary with an underlying probability of 99% between 0.0 and 1.3/100,000.

Standardized mortality ratio (SMR) 2003 - 2008: Males

Standardized mortality ratio (SMR) 2003 - 2008: Females

Figure 19b. Map of standardized mortality ratio (SMR, incl. DCO cases) by county averaged for period 2003 to 2008. According to their individual SMR values, the counties are displayed in different red and blue color temperatures where the fine white color indicates the population overall of 1.0 (males N=55, females N=39). Since cancer data are not available in some counties until 2007, the local SMR values were not calculated, and the map tiles show as shaded.

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 63,131 female residents (averaged) in the period from 2003 to 2008 a total of 1 women died from ureteral cancer. Therefore, the mean standardized mortality ratio (SMR) for this cancer type in this area can be calculated at 0.93. Though, the value of this parameter may vary with an underlying probability of 99% between 0.00 and 6.88, and is therefore not statistically striking.

Statistical Notes

In all tables and figures the respective reference values should be carefully considered. The incidence rates include diagnoses (with multiple primary), and death certificate only (DCO) cases. For mortality statistics patients, diagnoses and progressive course of disease are presented. In the calculations, all courses of disease are considered whereby progressions occurred and/or death certificate identified progressive cancers were ascertained. Additionally there are three groups of disease course to consider:

1. **All multiple primaries included**

   The mortality statistic describes the tumor-specific death, independent of any malignancy. The patient perspective, induced secondary malignancies, and the problem of multiple malignancies from the same primary tumor all have reasons for their inclusion.

2. **First singular primary** (no information about other prior or synchronous malignancy)

   The mortality statistic describes the tumor-related death for patients who have no therapeutic restrictions due to a previous or synchronous cancer. These statistics are comparable to studies that have exclusion criteria based on a second malignancy.

3. **Single primary** (no information about other prior, syn- or metachronous malignancy)

   The mortality statistic describes the tumor-specific death that occurs without any impact through secondary primaries, earlier, synchronous, later or induced. Precisely the difference between disease group 1 and 2 highlight the magnitude of the problem of secondary malignancies.

For this reason differences appear concerning official mono-causal mortality statistics. To judge the maximum deviation, 2 further tables are presented. In the first table the distribution of secondary malignancies before, at or after the described cancer are shown, that could be an alternative cause of death. In the second table, the age-specific mortality rates for all courses of disease, without designation of secondary malignancies are shown.

A previously minimally acknowledged statistic is the **age at death**, which allows for a good assessment of the quality of classification of the apparent tumor-specific death. For assumed tumor-independent deaths, the age of death should be estimated from the age of diagnosis and the normal life expectancy, whereas tumor-dependent deaths can be estimated from the age of diagnosis plus the average tumor-specific life expectancy. The comparison of different tumors demonstrates this association, if the causes of cancer and the competing cause of death are independent of each other (e.g. breast and colon versus head/neck and lung).

The index from mortality and incidence (Mortality-Incidence ratio, **MI-index**) is a statistic that allows for the evaluation of the quality of data. For diseases with poor prognoses, comparable values are obtained from all age groups, because to a large extent, the numerator and denominator contain the same cases. For tumors with a good prognosis, increasing and decreasing incidence and age-specific differences in prognosis can more strongly alter the MI- index. Additionally, attention should be paid to the confidence intervals where fewer cases are reported.

The complexity of problems identified here emphasizes the importance of relative survival data for the appropriate analysis of long term results.

As a measurement of the burden of disease, the number of potential life years loss due to premature deaths in a cohort can be calculated (**PYLL**, potential years of life lost, standardized per 100,000 persons or per European standard) as well as the average loss of life years per individual (**AYLL**, average years of life lost). Depending upon the analytic aim (health economy, prevention, health care research) different methods exist for the generation of these measurements. In the results presented here, the age for a premature death is considered to be before 70 years, according to the guidelines of the OECD and the WHO (as seen in the abbreviation PYLL-70 or AYLL-70).

Shortcuts

AYLL-70	Average years of life lost prior to age 70 given a person dies before that age
BRD-S	German standard population
DCO	Death certificate only
EAR	Excess absolute risk
	= excess cancer cases (O - E) per 10,000 person-years
ES	European standard population (old)
FRG	Federal Republic of Germany
GEKID	Association of Population-based Cancer Registries in Germany
	(Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V.)
LCL	Lower confidence limit
MI-index	Ratio between mortality and incidence
MCR	Munich Cancer Registry (Tumorregister München)
PYLL-70	Potential years of life lost prior to age 70 given a person dies before that age
SEER	Surveillance, Epidemiology, and End Results (USA)
SIR	Standardized incidence ratio
SMR	Standardized mortality ratio
UCL	Upper confidence limit
WS	World standard population

Recommended Citation

Munich Cancer Registry. Baseline statistics C66: Ureteral cancer [Internet]. 2014 [updated 2014 Mar 20; cited 2014 May 1]. Available from: http://www.tumorregister-muenchen.de/en/facts/base/base_C66__E.pdf

Copyright

The content of the public web site provided by the Munich Cancer Registry is available worldwide and free of charge. All documents are free to download, utilize, copy, print-out and distribute, providing that the MCR is referenced.

Disclaimer

The Munich Cancer Registry reserves the right to not be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.

Index of figures and tables